Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date
tags : Phase 3 save search
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
ALNY | $146.59 -0.62% 0.31% |
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
cardiac results phase 3
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CNCE | $4.57 6.03% 1.16% |
|
Health Technology
|
| O: 6.07%
H: 8.26%
C: -13.24%
ctp-543 for topline trial positive results phase 3
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
BHVN | $144.01 0.15% 0.0% |
|
Health Technology
|
| O: 0.25%
H: 1.91%
C: 0.92%
for trial phase 3
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
PYPD | $4.61 0.0% |
|
Health Technology
|
| O: 2.54%
H: 4.77%
C: -3.24%
trial enroll phase 3
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
Published: 2022-05-23 (Crawled : 08:00) - prnewswire.com
ASND | $95.07 4.37% 0.0% |
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial results growth hormone phase 3 topline
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $182.12 -0.09% 0.1% |
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
hypertension positive phase 3
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-19 (Crawled : 16:20) - ir.radiuspharm.com
RDUS | News | $10.205 0.94% -0.4% |
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
elacestrant trial publication group phase 3
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $104.5 |
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $52.62 -1.5% -0.41% |
|
Health Technology
| Email alert
Add to watchlist
REGN | $602.68 -1.6% 0.15% |
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $8.35 |
|
Health Technology
| Email alert
Add to watchlist
evkeeza children cholesterol trial phase 3 rare
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-20 (Crawled : 08:00) - prnewswire.com
RDUS | News | $10.205 0.94% -0.4% |
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
elacestrant trial publication group phase 3
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
Published: 2022-05-19 (Crawled : 00:00) - globenewswire.com
KRYS | $68.07 -0.66% 0.0% |
|
Health Technology
|
| O: 3.63%
H: 1.97%
C: 1.39%
for biotech phase 3
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
OCUP | $2.02 6.32% 7.37% |
|
Health Technology
|
| O: -15.14%
H: 13.51%
C: 10.27%
nyxol for topline eye trial positive results phase 3
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Published: 2022-05-19 (Crawled : 12:00) - globenewswire.com
ZEAL | $13.955 0.0% |
|
Health Technology
|
| O: 18.8%
H: 2.81%
C: -0.79%
pharma trial positive results phase 3
Aldeyra Therapeutics Announces that Post-Hoc Analysis of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
Published: 2022-05-18 (Crawled : 13:00) - biospace.com/
ALDX P | $3.875 5.3% -4.89% |
|
Health Technology
|
| O: 2.14%
H: 0.0%
C: -6.11%
for ocular trial therapeutics phase 3
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
Published: 2022-05-18 (Crawled : 12:20) - biospace.com/
IOBT | $5.1 5.59% -8.49% |
|
|
| O: -2.9%
H: 3.0%
C: -17.91%
io102 keytruda treatment melanoma biotech trial phase 3
Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification
Published: 2022-05-17 (Crawled : 18:00) - biospace.com/
KMDA | News | $4.61 0.0% |
|
Health Technology
|
| O: 1.68%
H: 3.0%
C: 2.07%
expansion six trial positive phase 3
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
ETTX | $2.2 -0.91% |
|
Health Technology
|
| O: 1.71%
H: 1.69%
C: -0.56%
conference trial therapeutics phase 3
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
LIFE | $2.88 0.7% 1.4% |
|
Health Technology
|
| O: 0.0%
H: 5.23%
C: 0.65%
atyr1923 pharma phase 3
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
Published: 2022-05-12 (Crawled : 19:00) - biospace.com/
SRRA | $54.955 0.08% 0.06% |
|
Health Technology
|
| O: -0.06%
H: 0.15%
C: 0.13%
presentation phase 3
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $153.14 0.53% 0.04% |
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
rinvoq disease response one phase 3
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
VERU | $12.85 -2.73% 0.0% |
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
LLY | News S | $327.27 0.51% 0.04% |
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin for authorization positive phase 3
Your saved searches
Save your searches and get alerts when important news are released.
Mentioned Today
ABBV | News | $153.14 0.53% 0.04% |
|
Health Technology
BNPQF | News | $50.78 |
|
Finance
BNPQY | News | $25.46 |
|
Finance and Insurance
BNPZY | News | $ 0% |
|
Finance and Insurance
CNXC | News | $147.67 1.63% -0.04% |
|
Information
CNXCV | News | $2.27 0% |
|
Commercial Services
DMYD | News | $16.21 0% |
|
Finance
DMYT | News | $22.76 0% |
|
Finance
DRE | News | $56.17 -2.23% 0.0% |
|
Finance
EPZM | News | $1.47 54.09% 7.97% |
|
Health Technology
FTRP | News | $0.81 1.25% 0.0% |
|
Health Care and Social Assistan...
HR | News | $27.23 1.38% 0.0% |
|
Finance
HTA | News | $27.7 -0.22% 0.0% |
|
Finance
IONQ | News | $4.83 -5.48% 2.07% |
|
Professional, Scientific, and T...
LLY | News 4 | $327.27 0.51% 0.04% |
|
Health Technology
OMC | News | $64.75 0.23% 0.0% |
|
Commercial Services
PACB | News | $5.3 -5.53% -1.78% |
|
Health Technology
PLD | News | $120.21 -1.94% 0.54% |
|
Finance
PSORF | News | $9.55 0% |
|
Consumer Services
RDUS | News | $10.205 0.94% -0.4% |
|
Health Technology
SNY | News | $52.62 -1.5% -0.41% |
|
Health Technology
SNYNF | News | $104.5 |
|
Health Technology
SREV | News | $1.45 -2.76% |
|
Technology Services
TUP | News 4 | $7.16 1.42% 0.0% |
|
Producer Manufacturing
USAK | News | $30.85 -0.48% -0.39% |
|
Transportation
WWE | News | $61.0 0.63% 0.0% |
|
Consumer Services
ZEN | News | $74.65 0.65% -0.07% |
|
Technology Services